Clinical Trial Search

Primary: Absolute Perihematoma Edema (aPHE) Volume Measured by Computed Tomography (CT) Scan After Intracerebral Hemorrhage (ICH) — 55.09; 52.50 mL — p=0.585

Primary: Mean Change From Baseline in Seconds to Withdraw Hand From Cold Pressor Laboratory Pain Task — 25.4; 33.9; 31.7; 36.7 seconds — p=0.61

Primary: Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* — 9.92; 11.73; 1.77; 11.93 milliseconds (msec)

Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants

Primary: Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period — 35.0; 23.1 Percentage of participants

Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants

Primary: Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS) — 1.0; 0.7; 0.1; 0.3 changes in scores on a scale — p=0.26

Primary: Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57 — 142.87; 143.03 Millimeters of…

Primary: Complete Response (CR) Defined as no Emesis and no Rescue Therapy — 13 Participants

Primary: Progression-free Survival (PFS) at 6 Months — 58.6 percentage of participants

Primary: Mucositis — 0.37; 2.84; 0.34; 2.87 score on a scale

Primary: Number of Participants With Any Improvement From Baseline in Mucosal Wave Grade — 14; 5 Participants

Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants

Primary: Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin — 0; 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) — 166; 171 Days — p=0.589